🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchCan we talk about how SLOW the FDA is Page 8

Can we talk about how SLOW the FDA is

KarenAZ_mom Mon, Apr 20, 2026 at 10:27 AM 38 replies 1,036 viewsPage 8 of 8
NicoleRaleigh
Member
356
1,567
Aug 2024
Raleigh, NC
May 27, 2026 at 6:34 PM#36
lucas_SP_BR said:
If you are going to change something, change one thing and give it long enough to express itself.

Bookmarking. The distinction being drawn above is the one nobody else makes. I will report back once I have actually tried it.

19 19InsuranceTom, WendyG_ATL, SaraMom3 and 16 others
Reply Quote Save Share Report
Dr.ReproEndo
Senior Member
1,890
8,901
Jan 2024
Scottsdale, AZ
May 29, 2026 at 8:10 PM#37

Clinical perspective, offered as context rather than as advice. Worth answering the question that was asked rather than the one behind it. The narrow version usually has an answer; the broad version usually does not, and answering the broad one is how a thread stops being useful.

18 18andrew_nyc, Dr.EndoEP, GraceAZ_72 and 15 others
Reply Quote Save Share Report
lori_vegas
Member
378
1,678
Aug 2024
Las Vegas, NV
May 31, 2026 at 9:44 PM#38
Dr.ReproEndo said:
Worth answering the question that was asked rather than the one behind it.

Can confirm. Same sequence, different timescale. The detail I would add is minor and it is already implied above.

Last edited: May 31, 2026 at 11:44 PM
17 17oliver_london, tane_welly, Dr.PathRoch and 14 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
mike_mealprep
Member
412
1,890
Jul 2024
Chicago, IL
Jun 2, 2026 at 11:18 PM#39
Dr.ReproEndo said:
Worth answering the question that was asked rather than the one behind it.

Adding the part of the answer the thread has not reached. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

16 16mel_PDX, Dr.AddMedPHL, newstart_MO and 13 others
Reply Quote Save Share Report
dan_philly
Member
456
2,123
Jul 2024
Philadelphia, PA
Jun 5, 2026 at 12:50 AM#40

The figures, for anyone assembling their own picture. Worth stating the units and the reference range whenever you post a number here. A large fraction of the apparent disagreement in these threads is two people using different units and both being right.

Last edited: Jun 5, 2026 at 3:50 AM
44 19EndoResFellow, PharmacoVig_BOS, SurmountFan_IN and 41 others
Reply Quote Save Share Report
1678

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register